ValuEngine downgraded shares of Trimel Pharmaceuticals (OTCMKTS:TRLPF) from a hold rating to a sell rating in a research note published on Sunday.

Trimel Pharmaceuticals (TRLPF) opened at $0.29 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.94 and a current ratio of 1.81. Trimel Pharmaceuticals has a 1 year low of $0.08 and a 1 year high of $0.40.

COPYRIGHT VIOLATION WARNING: “Trimel Pharmaceuticals (TRLPF) Cut to “Sell” at ValuEngine” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at

Trimel Pharmaceuticals Company Profile

Trimel Pharmaceuticals Corporation is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men’s health, women’s health and respiratory medicine. The Corporation holds a license for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Trimel Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trimel Pharmaceuticals Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.